Desenvolvimento reprodutivo de ratos machos expostos ao agente hipolipemiante rosuvastatina

• Autor(a) principal: Leite, Gabriel Adan Araújo [UNESP]
• Data de Publicação: 2014
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://hdl.handle.net/11449/113939
• topic: Hipolipemiantes; Reprodução; Toxicologia; Antilipemic agents

Dyslipidemias are frequently found in children due to obesity, bad eating habits and the lack of physical exercises. Rosuvastatin acts as an HMG-CoA reductase inhibitor and has been indicated to prevent cardiovascular diseases and to treat dyslipidemias due to its higher efficiency to reduce serum cholesterol concentrations. This study aimed to investigate initial sexual development and the possible reproductive adverse effects on sexual maturity due to juvenile male rats exposure to rosuvastatin during prepuberty. Three groups were formed with newly weaned rats (n= 20/per group): control, whose rats received saline solution 0.9%, rosuvastatin at doses of 3 or 10 mg/Kg daily by gavage, since post-natal day (PND) 21 until puberty onset. Part of each group (n=10/per group) was euthanized on PND55 and the remaining rats (n=10/per group) were maintained until sexual maturity and were euthanized on PND110. On PND55, we analyzed the hormonal concentrations, testicular and epididymal histology and the expression of androgen receptors (AR) on testis and epididymis. During sexual maturity, the parameters evaluated were sexual behavior, hormonal concentrations, sperm production, morphology and motility, besides testicular and epididymal histology and immunohistochemistry for AR. In the rosuvastatin-treated groups, the results demonstrated a trend towards a decrease in testosterone concentration, but below the significance level, as well as delays in both the age of puberty onset and in epididymal development. There were also testicular alterations that might be related to delayed puberty and decrease of serum testosterone. In the adulthood, the rosuvastatin-treated groups showed diminution in follicle-stimulating hormone (FSH), luteinizing hormone (LH) and testosterone concentrations, delay in the latency to the first penis intromission, pathologic alterations on testis and epididymis and decreased sperm ...